Last Updated: July 15, 2026

Litigation Details for Craig v. CenturyLink, Inc. (D. Minnesota 2018)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Craig v. CenturyLink, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Details for Craig v. CenturyLink, Inc. (D. Minnesota 2018)

Date Filed Document No. Description Snippet Link To Document
2018-02-05 External link to document
2018-02-05 191 Exhibit(s) C $800,000,000 $806,067,892 4/15/2013 $10,166,334 23 $442,015 100.10 …Communications International Inc Files Patent Application for Family Chat (Indian Patent … Qwest Communications International Inc. Patent Issued for Wireless Digital Video Recorders-- … Qwest Communications International Inc. Patent Issued for Wireless Digital Video Recorders-- … Qwest Communications International Inc. Patent Issued for Wireless Digital Video Recorders-- External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Craig v. CenturyLink, Inc. (0:18-cv-00296): Litigation Summary, Procedural Posture, and IP/Commercial Impact Analysis

Last updated: June 27, 2026

What happened in Craig v. CenturyLink, Inc., 0:18-cv-00296?

Executive summary: The case captioned Craig v. CenturyLink, Inc. | 0:18-cv-00296 proceeds as a federal civil action filed in 2018 against CenturyLink, Inc. The matter is tracked under docket number 0:18-cv-00296 and is evaluated through standard federal case management milestones: complaint, responsive pleadings, motion practice, and (if reached) discovery and dispositive motions.

Core case identifiers | Field | Value | |---|---| | Case name | Craig v. CenturyLink, Inc. | | Docket number | 0:18-cv-00296 | | Filing year | 2018 | | Defendant | CenturyLink, Inc. |

Claims, causes of action, and legal theories No pleadings, amended complaint, or dispositive-motion text is provided in the input. Without those record-level details, a complete litigation merits analysis (statute-by-statute or theory-by-theory) cannot be produced accurately.

Disposition and outcome No judgment, dismissal order, settlement notice, or termination docket entry is provided in the input. A reliable outcome summary (dismissal with or without prejudice, grant/denial of motion to dismiss, class certification, summary judgment, or settlement) cannot be stated.


What procedural stage is Craig v. CenturyLink at (and what does that imply)?

Short answer: The docket stage cannot be determined from the input alone.

What a stage-aware read typically covers

  • Status of pleadings (initial complaint vs. amended complaint)
  • Whether Rule 12(b) motions were filed and ruled on
  • Discovery scheduling order status
  • Whether dispositive motions (summary judgment) were filed
  • Whether the case was dismissed, settled, or proceeded to trial

Because none of these items are present in the provided information, stage-specific implications (timing risk for related claims, settlement likelihood, or litigation posture leverage) cannot be derived.


What motions and rulings matter most in Craig v. CenturyLink, Inc., 0:18-cv-00296?

Short answer: Not determinable from the input.

Motions that typically drive case economics

  • Motion to dismiss (Rule 12(b)(6))
  • Motion to compel discovery
  • Motion for protective order
  • Motion for class certification (if relevant)
  • Motion for summary judgment (if the case advanced)

Without docket entries or order text, the motion set and any ruling-level impact cannot be summarized.


How strong is CenturyLink’s litigation position in 0:18-cv-00296?

Short answer: Strength cannot be assessed without:

  • the asserted claims,
  • the allegations and factual record,
  • the court’s rulings,
  • and any legal defenses actually argued.

A credible strength analysis must anchor to ruling content (dismissal grounds, pleading sufficiency, evidentiary rulings, or statutory interpretation). None is included.


What claims are at issue in Craig v. CenturyLink, Inc. (and how do they affect damages and exposure)?

Short answer: Claims and damages exposure are not specified in the input.

Litigation exposure modeling depends on:

  • legal theory (contract, tort, statutory discrimination/consumer, wage/hour, telecom regulatory, privacy, etc.)
  • remedy sought (compensatory, punitive, injunctive relief, attorneys’ fees)
  • class or collective allegations
  • geographic scope

No complaint-level detail is included.


Does Craig v. CenturyLink, Inc. involve telecom regulatory issues or IP-like disputes?

Short answer: The input does not indicate the nature of the dispute.

CenturyLink litigation can touch multiple domains (telecom services, billing/collection, employment, consumer protection, regulatory compliance). A targeted analysis requires the complaint’s subject matter.


How does this case compare with other CenturyLink federal actions?

Short answer: Comparison cannot be performed without knowing the cause of action and procedural outcome for 0:18-cv-00296.

A meaningful comparison uses:

  • shared legal theories,
  • repeated fact patterns,
  • consistent outcomes or settlement ranges,
  • and court-specific trends.

None of those variables are available in the input.


Key Takeaways

  • The only reliable facts provided are the case name, defendant, docket number (0:18-cv-00296), and filing year (2018).
  • No complaint, motion, ruling, or disposition text is present, so an accurate litigation summary, posture assessment, or exposure analysis cannot be completed.

FAQs

1) What is the jurisdiction and court for Craig v. CenturyLink, Inc. 0:18-cv-00296?
Not provided in the input.

2) Was Craig v. CenturyLink dismissed, settled, or decided on the merits?
Not provided in the input.

3) What claims did Craig assert against CenturyLink?
Not provided in the input.

4) Did the court rule on any dispositive motions (Rule 12 or summary judgment)?
Not provided in the input.

5) Is there a related state-court case or arbitration tied to the federal action?
Not provided in the input.


References

(0:18-cv-00296 case docket information was not included in the input; no external sources were provided to cite.)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.